Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Glucagon Stimulation Test in Healthy Subjects
NCT05206149Phase 4Completed
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in hypopituitarism comparing Intranasal Glucagon with Placebo (2 arms). Primary endpoints: Change in serum ACTH levels between baseline and post-administration timepoints at 180 months, Change in serum cortisol levels between baseline and post-administration timepoints at 180 months and 2 more. Started Oct 2021; status: completed.
02
Drugs
glucagon
03
Conditions
hypopituitarism
Beyond the preview
Go deeper on NCT05206149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206149.